Skip to main content

Peer Review reports

From: Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Original Submission
20 Dec 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
11 Jan 2023 Reviewed Reviewer Report
18 Jan 2023 Reviewed Reviewer Report
3 Feb 2023 Author responded Author comments - Emile E. Voest
Resubmission - Version 3
3 Feb 2023 Submitted Manuscript version 3
14 Feb 2023 Reviewed Reviewer Report
17 Feb 2023 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
20 Feb 2023 Editorially accepted
4 Mar 2023 Article published 10.1186/s12885-023-10663-2

You can find further information about peer review here.

Back to article page